India, July 9 -- Oryzon Genomics, S.A. (ORY.MC, ORYZF), a clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office or USPTO has granted U.S. Patent No. 12,673,044, entitled "Methods of treating borderline personality disorder" for Vafidemstat in Borderline Personality Disorder or BPD.
Oryzon focuses on the development of epigenetics-based therapeutics for the central nervous system, oncology, and haematology disorders.
The received patent is expected to expire in March 2043, including 1,095 days of Patent Term Adjustment (PTA) granted to compensate for delays during patent prosecution.
The granted claims cover methods to treat non-aggressive symptoms of borderline personality disorder (BPD) u...